Listing & Compliance Notices

Notable Labs, Ltd. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(ii)).

“February 28, 2023, VBL received confirmation that Nasdaq had approved the Transfer, and VBL’s ordinary shares will begin trading on The Nasdaq Capital Market effective with the open of trading on March 2, 2023. VBL’s ordinary shares continue to trade under the symbol “VBLT”. The Nasdaq Capital Market operates in substantially the same manner as The Nasdaq Global Market, with issuers listed on The Nasdaq Capital Market tier required to meet certain financial and corporate governance requirements to qualify for continued listing. On February 28, 2023, VBL received confirmation that Nasdaq has de”

SIFCO INDUSTRIES INC received a nyse_american deficiency notice notice regarding late filing (rules 1007).

“February 22, 2023, SIFCO Industries, Inc. (the “Company” or “SIFCO”) received a notice from the NYSE American LLC (the “NYSE American”) indicating that, due to the delay in the filing of its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”) (as reported on the Form 12b-25 filed by the Company on February 14, 2023), the Company is not in compliance with the continued listing standards of the NYSE American and is subject to the procedures and requirements set forth in Section 1007 of the NYSE American Company Guide. The Company expects to complete the prepara”

ALKALINE WATER Co INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 22, 2023, The Alkaline Water Company Inc. (the "Company") received a letter (the "Letter") from the Listing Qualifications Department of The Nasdaq Stock Market (the "Nasdaq"), notifying the Company that since the Company had not yet filed its Form 10-Q for the period ended December 31, 2022, it no longer complies with the Nasdaq's Listing Rule 5250(c)(1) (the "Rule") relating to the Company's obligation to file periodic financial reports for continued listing. The Company has since satisfied this obligation by filing its delinquent Form 10-Q on February 28, 2023.”

GT Biopharma, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 22, 2023, GT Biopharma, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, and its common stock”

Vinco Ventures, Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5810(c)(2)(A)).

“February 21, 2023, Company received staff determination letter from Nasdaq. On January 4, 2023, Staff notified the Company that since it had not held an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year end, it no longer complied with our Listing Rules (the “Rules”) for continued listing. In that regard, the Company was required to submit its plan by February 20, 2023, which was timely submitted. However, pursuant to Listing Rule 5810(c)(2)(A), this deficiency serves as additional and separate basis for delisting. The letter is formal notification that”

Lucira Health, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“February 23, 2023, the Company received written notice (the “Delisting Notice”) from the staff of the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Filing and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filing and associated public interest concerns raised by it, concerns regarding the residual equity interest of the existing listed securities holders and co”

Singularity Future Technology Ltd. received a nasdaq delisting notice notice regarding late filing.

“February 21, 2023, Singularity Future Technology Ltd. (the “Company”) received an additional staff determination notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), advising that it had not received the Company’s Form 10-Q for the quarterly period ended December 31, 2022, which served as an additional basis for delisting the Company’s securities and that the Nasdaq Hearings Panel (the “Panel”) will consider the additional deficiency in rendering a determination regarding the Company’s continued listing on Nasdaq. The Company has submitted”

STRATA Skin Sciences, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 27, 2023 STRATA Skin Sciences, Inc. (the “Company”) received notice from The NASDAQ Stock Market (“Nasdaq”) that, STRATA has regained compliance with the Nasdaq listing requirements as required by Rule 5550(a)(2) r egarding the Company’s minimum bid price , and the Company will continue to trade on Nasdaq.”

ENERGY FOCUS, INC/DE received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 21, 2023, the Company received written notification (the “Notification”) from Nasdaq stating that the Company had not regained compliance with the Rule and was ineligible to obtain a second 180 calendar day period to regain compliance because it did not meet the Nasdaq Capital Market’s minimum $5,000,000 Stockholders’ Equity initial listing requirement as of September 30, 2022. Pursuant to the Notification, the Company’s common stock is subject to delisting from Nasdaq pending the Company’s opportunity to request a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company in”

SOLIGENIX, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“February 21, 2023, the Company received a letter (the “Continued Listing Letter”) from Nasdaq, stating that the Panel granted the Company’s request to continue its listing on Nasdaq, on the condition that (1) on February 24, 2023, the Company shall have demonstrated compliance with the Minimum Bid Price Requirement, by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions; and (2) on or before March 31, 2023, the Company shall demonstrate compliance with the Stockholders’ Equity Requirement. The Continued Listing Letter is consistent with”

SOLIGENIX, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1)).

“February 21, 2023, the Company received a letter (the “Continued Listing Letter”) from Nasdaq, stating that the Panel granted the Company’s request to continue its listing on Nasdaq, on the condition that (1) on February 24, 2023, the Company shall have demonstrated compliance with the Minimum Bid Price Requirement, by evidencing a closing bid price of $1.00 or more per share for a minimum of ten consecutive trading sessions; and (2) on or before March 31, 2023, the Company shall demonstrate compliance with the Stockholders’ Equity Requirement. The Continued Listing Letter is consistent with”

Laser Photonics Corp received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“February 17, 2023, the registrant (“Laser Photonics” or the “Company”) received a notice from Nasdaq Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") stating that the Company no longer complies with Nasdaq’s audit committee requirement under Nasdaq’s Listing Rule 5605 following the resignation of Glenn Peterson from the Company’s board of directors and audit committee effective December 16, 2022. Nasdaq advised Laser Photonics that in accordance with Nasdaq’s Listing Rule 5605(c)(4) the Company has a cure period to regain compliance (i) until the earlier of the Compa”

EXICURE, INC. received a nasdaq deficiency notice notice regarding board independence (rules 5605, 5605(d)(4)).

“February 21, 2023, Exicure, Inc. (the “Company”) received notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company is no longer in compliance with Nasdaq’s compensation committee requirements as set forth in Nasdaq Listing Rule 5605 as a result of the previously disclosed resignation of Jeffrey L. Cleland, Ph.D., effective February 10, 2023 . Nasdaq Rule 5605 requires the compensation committee of the board of directors to be comprised of at least two independent directors (the “Listing Requirement for Compensation Committee”). Pursuant to Nasdaq Listing Rules 5605(d)(4), the Compan”

ObsEva SA received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 23, 2023, the Company notified The Nasdaq Stock Market LLC (“Nasdaq”) of its inability to comply with Nasdaq Listing Rule 5450(a)(1) (the “Bid Price Rule”) because the bid price of the Company’s common shares has not closed at or above $1.00 per share for a minimum of ten consecutive business days. As previously reported, on September 12, 2022, the Company received notice from the Listing Qualifications Staff of Nasdaq indicating that the Company was not in compliance with the Bid Price Rule and the Company’s securities were subject to delisting unless, among other things, the Company”

PetVivo Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 17, 2023, PetVivo Holdings, Inc. (the “Company”) received written notice (“ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) stating that the Company no longer complies with the minimum stockholders’ equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on The Nasdaq Capital Market because the Company’s stockholders’ equity, as reported in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2022, has fallen below $2.5 million. The Notice also indicates that the Company does not meet the alternative compliance standards rel”

Evolve Transition Infrastructure LP received a nyse_american extension granted notice regarding minimum bid price (rules 1003(f)(v)).

“February 21, 2023 stating that the Partnership’s compliance plan has been accepted and that the Partnership has been granted a targeted completion date of June 6, 2024 to implement its plan and regain compliance. By June 6, 2024, the Partnership must either be in compliance or must have made progress that is consistent with the plan during the plan period. Failure to meet the requirements to regain compliance could result in the initiation of delisting proceedings. The Partnership remains subject to the 12.27.22 Notice. Pursuant to Section 1003(f)(v) of the Company Guide, the Partnership’s con”

Evolve Transition Infrastructure LP received a nyse_american extension granted notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“February 21, 2023 stating that the Partnership’s compliance plan has been accepted and that the Partnership has been granted a targeted completion date of June 6, 2024 to implement its plan and regain compliance. By June 6, 2024, the Partnership must either be in compliance or must have made progress that is consistent with the plan during the plan period. Failure to meet the requirements to regain compliance could result in the initiation of delisting proceedings. The Partnership remains subject to the 12.27.22 Notice. Pursuant to Section 1003(f)(v) of the Company Guide, the Partnership’s con”

HUMANIGEN, INC received a nasdaq delisting notice notice regarding market value.

“February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St”

HUMANIGEN, INC received a nasdaq delisting notice notice regarding stockholders equity.

“February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St”

HUMANIGEN, INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 21, 2023, the Company received a letter from the Staff of Nasdaq notifying the Company that it had not regained compliance with the minimum bid price requirement as of February 20, 2023 and that it was not eligible for a second 180 day extension period. The Nasdaq Staff’s letter specifically noted that the Company does not comply with the stockholders’ equity initial listing requirement for The Nasdaq Capital Market. The total market value of the Company’s listed securities also remains below the $35 million requirement for continued listing on The Nasdaq Capital Market. The Nasdaq St”

DMK PHARMACEUTICALS Corp received a nasdaq hearing update notice regarding minimum bid price (rules 5500(a)(2)).

“February 21, 2023, Adamis Pharmaceuticals Corporation (“Adamis” or the “Company”) received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) had granted the Company’s request for continued listing on The Nasdaq Capital Market, subject to the Company evidencing compliance with all applicable criteria for continued listing, including the $1.00 bid price requirement set forth in Nasdaq Listing Rule 5500(a)(2) (the “Rule”), by no later than June 26, 2023 (the “Compliance Period”). The Company’s continued listing is subject to the Comp”

Polished.com Inc. received a nyse_american extension granted notice regarding late filing (rules 134, 1101, 1007).

“does not complete its Delayed Filings with the Securities and Exchange Commission by the end of the maximum 12-month cure period on August 22, 2023, Exchange staff will initiate delisting proceedings as appropriate. The Company may appeal an Exchange staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide. The Company is committed to filing the Delayed Reports to achieve compliance with the Exchange’s requirements and intends to file the Delayed Reports by July 31, 2023. The Company also intends to file all subsequent reports, including the Company’s Annu”

Greencity Acquisition Corp received a nasdaq compliance regained notice regarding shareholders (rules 5550(a)(3)).

“February 21, 2023, the Company received a letter from Nasdaq stating, based on the information submitted by the Company on February 18, 2023, Nasdaq has determined that the Company now complies with the filing criteria established in Nasdaq Listing Rule 5550(a)(3). SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf as of February 23, 2023 by the undersigned hereunto duly authorized. Greencity Acquisition Corporation By: /s/ Jinlong Liu Jinlong Liu Chief Executive Officer”

electroCore, Inc. received a nasdaq hearing update notice regarding minimum bid price (rules 5550(a)(2)).

“February 16, 2023, the Company received written notice from the Panel of its decision granting the Company’s request to extend the period for the Company to regain compliance with the Bid Price Rule until March 13, 2023. The Panel noted that in light of completion of the Reverse Stock Split prior to the issuance of the Panel’s decision, the Company was likely to regain compliance with the Bid Price Rule by March 1, 2023. The Panel’s decision is subject to the Company’s continued compliance with applicable Nasdaq listing requirements and may be reviewed by the Nasdaq Listing and Hearing Review”

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 16, 2023, the Company received a notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “ Form 10-Q ”), the Company remains in non-compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of all required periodic financial reports with the Securities and Exchange Commission. As previously disclosed on Form 8-Ks filed with the Securities and Exchange Commission, on October 17, 2022 and November 23, 2022, respectively, the Co”

CYREN Ltd. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“law, and commence applicable liquidation, assignment and/or insolvency proceedings for each of the subsidiaries of the Company. In light of the planned liquidation, on the same day, the Company received written notice from Nasdaq, advising it that based upon Nasdaq’s review and pursuant to Listing Rule 5101, 5110(b) and IM-5101-1, Nasdaq has determined to delist the Company’s securities from The Nasdaq Stock Market. The Company does not plan to appeal Nasdaq’s determination. Therefore, the Company expects, based on Nasdaq’s written notice, that the trading of the Company’s ordinary shares wil”

U S GLOBAL INVESTORS INC received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 16, 2023, U.S. Global Investors, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”) within the prescribed time period, the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1). In accordance with Nasdaq Listing Rules, the Company has 60 calendar days to submit a plan to regain compliance. Following receip”

AIRWA INC. received a nasdaq noncompliance notice notice regarding other (rules 5605).

“January 12, 2023, Nasdaq notified the Company that due to the resignations from the Company’s board, audit committee and compensation committee on November 17, 2022, the Company no longer complies with Nasdaq’s independent director, audit committee and compensation committee requirements as set forth in Listing Rule 5605. In that regard, the Company was required to submit its plan of compliance by February 27, 2023. However, pursuant to Listing Rule 5810(c)(2)(A), these deficiencies serve as additional and separate basis for delisting and the Company will be required to address these concerns”

AIRWA INC. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“February 14, 2023, Connexa Sports Technologies Inc. (the “ Company ”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that, due to the Company’s failure, in violation of Listing Rule 5250(c)(1), to file its (i) Annual Report on Form 10-K with respect to the fiscal year ended April 30, 2022 and (ii) Quarterly Reports on Form 10-Q for the periods ended July 31, 2022 and October 31, 2022 (collectively, the “ Delinquent Filings ”), by February 13, 2023 (the due date for filing the Delinquent Filings pursuant to an exception to Nas”

SVF Investment Corp. 2 received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“January 19, 2023, SVF Investment Corp. 2 (the “Company”) received a notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was deficient in meeting the requirements of Listing Rule 5620(a), which requires the Company to hold an annual meeting of shareholders no later than one year after the end of the Company’s 2021 fiscal year-end. In accordance with Nasdaq Listing Rule 5810(c)(2)(G), the Company has 45 calendar days (or until March 5, 2023) (the “Compliance Period”) to submit a plan to regain compliance and, if Nasdaq accepts the plan, Nasdaq may grant the Company up”

Vinco Ventures, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 14, 2023, Vinco Ventures, Inc. (the “Company”) received a Staff Determination letter (the “Letter”) from Nasdaq. The Letter states that on August 19 and November 17, 2022, Staff notified the Company that it did not comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) (the “Rule”) because it had not filed its Form 10-Q for the period ended June 30, 2022, and its Form 10-Q for the period ended September 30, 2022 (the “Delinquent Filings”). Staff granted the Company an exception until January 31, 2023, to regain compliance with the Rule. Subsequently, on January”

SONIC FOUNDRY INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 14, 2023, Sonic Foundry, Inc. (the “Company”) was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that it is not in compliance with the requirement to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Since its Form 10-Q for the period ended December 31, 2022, reported stockholders’ equity of $922,000, and as of February 10, 2023, the Company does not meet the alternatives of market value of listed securities or net income, as set forth in Nasdaq Listing Rule 5550(b)(1), the Company no longer complies with the Rule. In accordance with Nasdaq Listing R”

TruGolf Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5450(b)(2)).

“January 22, 2023 indicating that the Company, following the stockholder redemptions at its last stockholder meeting, is not in compliance with Listing Rule 5450(b)(2), due to the Company’s failure to meet the minimum 1,100,000 publicly held shares requirement for continued listing on the Nasdaq Global Market. Upon the transfer of listing of the Company’s securities on the Nasdaq Capital Market on February 17, 2023, such deficiency would be resolved. On February 16, 2023, the Company issued a press release announcing its listing transfer to the Nasdaq Capital Market, which is attached as Exhibi”

Vintage Wine Estates, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“February 13, 2023, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company has not filed its Quarterly Report on Form 10-Q for the period ended December 31, 2022 (the “Form 10-Q”) within the prescribed time period, the Company is not in compliance with the timely filing requirement for continued listing under Nasdaq Listing Rule 5250(c)(1). The Nasdaq notification letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. While the notification letter provides”

Quadro Acquisition One Corp. received a nasdaq deficiency notice notice regarding audit committee (rules 5605, 5605(c)(4)).

“February 13, 2023, Kismet Acquisition Two Corp., a Cayman Islands exempted company (the “Company”), received a deficiency notice from the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, as a result of the resignation of Verdi Israelyan from the board of directors of the Company (the “Board”) and the audit committee of the Board (“Audit Committee”) on September 5, 2022, the Company is no longer in compliance with the continued listing requirements set forth in Nasdaq Listing Rule 5605 regarding the composition of the Audit Committee, because the Audit Committee is now comprised of on”

View, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“February 13, 2023, View, Inc., a Delaware corporation (“View” or the “Company”), received a notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 calendar days, or until August 14, 2023, to regain compliance. The Notice states that to regain compliance, the bid”

ABVC BIOPHARMA, INC. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“August 19, 2022, ABVC BioPharma, Inc. (the “ Company ”) filed a Current Report on Form 8-K to report that it received a deficiency letter from the Nasdaq Listing Qualifications Department (the “ Staff ”) of the Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock was below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (“ Rule 5550(a)(2) ”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Compan”

Mobile Infrastructure Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5550(a)(3)).

“February 13, 2023, Fifth Wall Acquisition Corp. III (the “Company”) received a written notice (the “Notice”) from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Listing Rule 5550(a)(3) (the “Minimum Public Holders Rule”), which requires the Company to have at least 300 public holders for continued listing on the Nasdaq Capital Market (the “Minimum Public Holders Rule”). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the C”

Hyzon Motors Inc. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“and will notify the Company within this 15 calendar day period whether the Company’s request for a stay pending the hearing will be granted. The date for the delisting hearing is set for March 16, 2023. At the hearing, the Company will present its plan to regain compliance with Nasdaq Listing Rule 5250(c)(1) and request the continued listing of its securities on The Nasdaq Capital Market pending such compliance.”

Acorda Therapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price.

“February 14, 2023, the Company received notice from Nasdaq granting the Company’s request to extend the period for the Company to regain compliance with the Minimum Bid Requirement until June 20, 2023. The Nasdaq Hearings Panel’s decision is subject to the Company’s continued compliance with applicable Nasdaq listing requirements and may be reviewed by the Nasdaq Listing and Hearing Review Council on its own within 45 days. The Company will actively monitor the closing bid price of its common stock and evaluate available options to regain compliance with the Minimum Bid Requirement, including”

LEE ENTERPRISES, Inc received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 8, 2023, Lee Enterprises, Incorporated (the “Company”) received a notification letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on From 10-Q for the quarter ended December 25, 2023 (the “2023 Q1 Form 10-Q”), the Company is not in compliance with the timely filing requirements for continued listing under Nasdaq Listing Rule 5250(c)(1). The Company filed a Notification of Late Filing on Form 12b-25 on February 6, 2023, stating it was unable to file the 2023 Q1 Fo”

CONTRAFECT Corp received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“February 8, 2023, the Staff notified the Company that the Staff had determined that, as of February 7, 2023, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days and that, consistent with Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”), the Staff was providing notice of an additional and separate basis to delist the Company’s securities from the Nasdaq Capital Market for failure to comply with the Low Priced Stocks Rule relating to the Bid Price Requirement. The Panel will consider this matter in rendering its determination”

CONTRAFECT Corp received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“January 20, 2023, the staff (“Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) informed ContraFect Corporation (the “Company”) that the Staff had determined to deny the Company’s request for continued listing on the Nasdaq Capital Market (the “Staff Determination”) in connection with its failure to satisfy the continued listing requirement under Nasdaq Listing Rule 5550(b)(1) for the Nasdaq Capital Market. The Company subsequently requested a hearing before a Nasdaq Hearings Panel (“Panel”) to appeal the Staff Determination, which was granted and is scheduled to occur in March 2023. In additi”

REED'S, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“viously disclosed, after a hearing with a Nasdaq panel on September 28, 2022, Reed’s was given until February 13, 2023 to regain compliance with the requirement to maintain a minimum bid price of $1.00 per share for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (“Bid Price Rule”), and the $2.5 million minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(b)(1) (“Minimum Stockholders’ Equity Rule”). Reed’s achieved compliance with the Bid Price Rule after effecting a”

Sorrento Therapeutics, Inc. received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).

“ase No. 23-90085) (the “Chapter 11 Cases”). On February 13, 2023, the Company received written notice (the “Delisting Notice”) from the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, as a result of the Chapter 11 Filings and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company’s common stock will be delisted from Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced the Chapter 11 Filings and associated public concerns raised by them, concerns regarding the residual equity interest of the”

Latch, Inc. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“February 7, 2023, Latch, Inc. (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process that could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the “SEC”). The Staff Dete”

Insight Molecular Diagnostics Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)(ii)).

“February 7, 2023. The Company’s common stock continues to trade under the symbol “OCX”. The Nasdaq Capital Market operates in substantially the same manner as The Nasdaq Global Market, with issuers listed on The Nasdaq Capital Market tier required to meet certain financial and corporate governance requirements to qualify for continued listing. On February 7, 2023, the Company received confirmation that Nasdaq has determined that the Company is eligible for an additional 180-calendar day period to regain compliance by meeting the minimum bid price requirement. The minimum bid price requirement”

Glucotrack, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“February 7, 2023, Nasdaq issued a letter to the Company granting an extension until May 22, 2023 to obtain compliance with the Listing Rule 5550(b) (the “Rule”), which requires a minimum $2,500,000 stockholders’ equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations, notice of noncompliance with which was provided by Nasdaq to the Company on November 22, 2022. Nasdaq has granted the Company an extension to comply through either one or both of an acquisition or equity capital raise on or before May 22, 2023.”

PLx Pharma Winddown Corp. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)).

“February 7, 2023, PLx Pharma Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) regarding its noncompliance with Nasdaq Listing Rule 5605(c)(2), which requires, among other things, that the Audit Committee (the “Audit Committee”) of the Board of Directors of the Company (the “Board”) be comprised of a minimum of three independent directors. As previously disclosed, John W. Hadden II ceased serving on the Board and its committees as of January 19, 2023, and as a result, the Company’s Audit Committee is currently comp”

HeartSciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 8, 2023, the Company received a letter from Nasdaq in which it stated, that based on the Company's submission of its plan of compliance to Nasdaq, Nasdaq has determined to grant the Company an extension of time to regain compliance with Nasdaq Listing Rule 5550(b)(1) until June 19, 2023. The Company must furnish to the SEC and Nasdaq a publicly available report (e.g. a Form 8-K) which report, among other things, includes a description of the completed transaction or event that enabled the Company to satisfy the stockholders' equity requirement for continued listing. After filing the p”